[go: up one dir, main page]

JP2010518061A5 - - Google Patents

Download PDF

Info

Publication number
JP2010518061A5
JP2010518061A5 JP2009548738A JP2009548738A JP2010518061A5 JP 2010518061 A5 JP2010518061 A5 JP 2010518061A5 JP 2009548738 A JP2009548738 A JP 2009548738A JP 2009548738 A JP2009548738 A JP 2009548738A JP 2010518061 A5 JP2010518061 A5 JP 2010518061A5
Authority
JP
Japan
Prior art keywords
salt according
salt
oxazol
ylmethyl
benzyloxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009548738A
Other languages
Japanese (ja)
Other versions
JP5373634B2 (en
JP2010518061A (en
Filing date
Publication date
Priority claimed from GBGB0702385.6A external-priority patent/GB0702385D0/en
Priority claimed from GBGB0702416.9A external-priority patent/GB0702416D0/en
Application filed filed Critical
Priority claimed from PCT/GB2008/000434 external-priority patent/WO2008096149A2/en
Publication of JP2010518061A publication Critical patent/JP2010518061A/en
Publication of JP2010518061A5 publication Critical patent/JP2010518061A5/ja
Application granted granted Critical
Publication of JP5373634B2 publication Critical patent/JP5373634B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (9)

[２−(４−クロロ−ベンジルオキシ)−エチル]−[２−((Ｒ)−シクロヘキシル−ヒドロキシ−フェニル−メチル)−オキサゾール−５−イルメチル]−ジメチル−アンモニウムナパジシル酸塩。   [2- (4-Chloro-benzyloxy) -ethyl]-[2-((R) -cyclohexyl-hydroxy-phenyl-methyl) -oxazol-5-ylmethyl] -dimethyl-ammonium napadisylate. [２−(４−クロロ−ベンジルオキシ)−エチル]−[２−((Ｒ)−シクロヘキシル−ヒドロキシ−フェニル−メチル)−オキサゾール−５−イルメチル]−ジメチル−アンモニウムヘミ−ナフタレン−１,５−ジスルホン酸塩である、請求項１に記載の塩。   [2- (4-Chloro-benzyloxy) -ethyl]-[2-((R) -cyclohexyl-hydroxy-phenyl-methyl) -oxazol-5-ylmethyl] -dimethyl-ammonium hemi-naphthalene-1,5- The salt of claim 1 which is a disulfonate. 少なくとも次の特徴的Ｘ線粉末回折ピーク(２θ度で示す)を示す、請求項２に記載の塩：
５.３、１０.５、１５.８および１６.５、または
５.３、１０.５、１５.８、１６.５、１８.６および１９.４または
５.３、１０.５、１５.８、１６.５、１８.６、１９.４、１９.７および２０.３または
５.３、１０.５、１５.８、１６.５、１７.８、１８.６、１９.４、１９.７、２０.４および２１.７。 The salt according to claim 2, which exhibits at least the following characteristic X-ray powder diffraction peaks (shown in 2θ degrees):
5.3, 10.5, 15.8 and 16.5, or 5.3, 10.5, 15.8, 16.5, 18.6 and 19.4 or 5.3, 10.5, 15 .8, 16.5, 18.6, 19.4, 19.7 and 20.3 or 5.3, 10.5, 15.8, 16.5, 17.8, 18.6, 19.4 19.7, 20.4 and 21.7. 図１と実質的に同じＸ線粉末回折パターンを有する、請求項３に記載の塩。   4. A salt according to claim 3, having an X-ray powder diffraction pattern substantially the same as in FIG. 無水和物である、請求項１〜４のいずれかに記載の塩。   The salt according to any one of claims 1 to 4, which is a non-hydrate. 請求項１〜５のいずれかに記載の塩を薬学的に許容されるアジュバント、希釈剤または担体と共に含む、医薬組成物。   A pharmaceutical composition comprising the salt according to any one of claims 1 to 5 together with a pharmaceutically acceptable adjuvant, diluent or carrier. 治療において使用するための、請求項１〜５のいずれかに記載の塩。   A salt according to any one of claims 1 to 5 for use in therapy. 慢性閉塞性肺疾患の処置用医薬の製造における、請求項１〜５のいずれかに記載の塩の使用。   Use of the salt according to any one of claims 1 to 5 in the manufacture of a medicament for the treatment of chronic obstructive pulmonary disease. 慢性閉塞性肺疾患の処置方法であって、請求項１〜５のいずれかに記載の塩をかかる処置を必要とする患者に投与することを含む、方法。A method for treating chronic obstructive pulmonary disease, comprising administering a salt according to any of claims 1-5 to a patient in need of such treatment.
JP2009548738A 2007-02-07 2008-02-06 Napadisilate of muscarinic M3 antagonist Expired - Fee Related JP5373634B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0702385.6 2007-02-07
GBGB0702385.6A GB0702385D0 (en) 2007-02-07 2007-02-07 New combination
GB0702416.9 2007-02-07
GBGB0702416.9A GB0702416D0 (en) 2007-02-07 2007-02-07 New combination
PCT/GB2008/000434 WO2008096149A2 (en) 2007-02-07 2008-02-06 Napadisylate salt of a muscarinic m3 antagonist

Publications (3)

Publication Number Publication Date
JP2010518061A JP2010518061A (en) 2010-05-27
JP2010518061A5 true JP2010518061A5 (en) 2011-03-10
JP5373634B2 JP5373634B2 (en) 2013-12-18

Family

ID=39485211

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009548738A Expired - Fee Related JP5373634B2 (en) 2007-02-07 2008-02-06 Napadisilate of muscarinic M3 antagonist

Country Status (13)

Country Link
US (1) US7846955B2 (en)
EP (1) EP2118078A2 (en)
JP (1) JP5373634B2 (en)
KR (1) KR20090119757A (en)
AU (1) AU2008212673B2 (en)
BR (1) BRPI0807004A2 (en)
CA (1) CA2675629A1 (en)
EC (1) ECSP099566A (en)
IL (1) IL199909A0 (en)
MX (1) MX2009008364A (en)
NZ (1) NZ578475A (en)
RU (1) RU2459810C2 (en)
WO (1) WO2008096149A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0516313D0 (en) * 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
MX2010012189A (en) 2008-05-13 2011-03-02 Astrazeneca Ab Quinuclidine derivatives as muscarinic m3 receptor antagonists.
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
CN104039369B (en) 2011-07-20 2017-06-16 布莱阿姆青年大学 Hydrophobicity plug draws Jining compound and the device comprising the compound
US11524015B2 (en) 2013-03-15 2022-12-13 Brigham Young University Methods for treating inflammation, autoimmune disorders and pain
CN105209465A (en) 2013-03-15 2015-12-30 布莱阿姆青年大学 Methods for treating inflammation, autoimmune disorders and pain
US11690855B2 (en) 2013-10-17 2023-07-04 Brigham Young University Methods for treating lung infections and inflammation
US20150203527A1 (en) 2014-01-23 2015-07-23 Brigham Young University Cationic steroidal antimicrobials
WO2016172534A1 (en) * 2015-04-22 2016-10-27 Savage Paul B Cationic steroidal antimicrobial salts
US10226550B2 (en) 2016-03-11 2019-03-12 Brigham Young University Cationic steroidal antimicrobial compositions for the treatment of dermal tissue
US10959433B2 (en) 2017-03-21 2021-03-30 Brigham Young University Use of cationic steroidal antimicrobials for sporicidal activity
EP3694839B1 (en) * 2017-10-13 2022-07-27 Treeway TW001 B.V. Edaravone salt
US12186328B2 (en) 2019-05-23 2025-01-07 Brigham Young University Use of CSA compounds to stimulate stem cells and hair growth
US11485567B2 (en) * 2020-04-09 2022-11-01 Shi Chia Lin Industry Co., Ltd. Coaxial container for dispensing a tubular product

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0733332B2 (en) * 1985-11-19 1995-04-12 富山化学工業株式会社 Dementia symptom improvement / therapeutic agent
EP0307141B1 (en) * 1987-09-10 1993-01-13 MERCK SHARP & DOHME LTD. Oxazoles and thiazoles for the treatment of senile dementia
GB9603755D0 (en) * 1996-02-22 1996-04-24 Pfizer Ltd Therapeutic agents
GB0516313D0 (en) * 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
WO2008017827A2 (en) * 2006-08-08 2008-02-14 Argenta Discovery Limited Azole and thiazole derivatives and their uses

Similar Documents

Publication Publication Date Title
JP2010518061A5 (en)
JP2012532874A5 (en)
JP2008539268A5 (en)
JP2013509429A5 (en)
JP2009529541A5 (en)
JP2013525444A5 (en)
JP2009541216A5 (en)
JP2009502743A5 (en)
JP2007504174A5 (en)
JP2014528901A5 (en)
JP2008539267A5 (en)
JP2015145426A5 (en)
JP2014530220A5 (en)
IL250439A0 (en) Use of fingolimod, or a phosphate derivative thereof or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of multiple sclerosis
JP2014503593A5 (en)
JP2012508215A5 (en)
JP2009530288A5 (en)
JP2010529118A5 (en)
JP2014502641A5 (en)
RU2009133262A (en) NAPADISILATE SALT OF MUSCARIN MZ-RECEPTOR ANTAGONIST
JP2013519675A5 (en)
JP2013522326A5 (en)
JP2015516419A5 (en)
JP2012512164A5 (en)
JP2015510916A5 (en)